Relatlimab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Relatlimab. Educational only — not medical advice.
Labeled uses
OPDUALAG™ is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.
Source: FDA labeling via NIH DailyMed (set b22c9d83…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.